Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Lung Carcinoma Metastatic to the Breast: A Comprehensive Analysis of Clinical Presentation, Morphologic, and Molecular Features, With Emphasis on Diagnostic Pitfalls.
Hashmi AA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality control.
Gray ER et al.
Translational Oncology, 2025
Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.
Ianniello M et al.
Journal of Translational Medicine, 2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
Genomic profiling unlocks new treatment opportunities for ampullary carcinoma.
Fabregat-Franco C et al.
Esmo Open, 2025
Genetic alterations affect immune contexture of non-small cell lung cancer: Ukrainian study.
Kozakov D et al.
Frontiers in Medicine, 2025
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples.
Redegalli M et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, 2023
Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
Fuentes-Antrás J et al.
International Journal of Molecular Sciences, 2023
Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.
Kim SH et al.
Journal of Pathology and Translational Medicine, 2023
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer-Data from Daily Practice.
Knetki-Wróblewska M et al.
Current Oncology (toronto, Ont.), 2022
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
Paliogiannis P et al.
Bmc Pulmonary Medicine, 2022
Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
Wang D et al.
Frontiers in Immunology, 2022
Papillary renal neoplasm with reverse polarity: A clinicopathological and molecular genetic characterization of 16 cases with expanding the morphologic spectrum and further support for a novel entity.
Shen M et al.
Frontiers in Oncology, 2022
Genomic landscape of lung cancer in the young.
Ruiz R et al.
Frontiers in Oncology, 2022
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV et al.
Journal for Immunotherapy of Cancer, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U et al.
European Journal of Cancer (oxford, England : 1990), 2021
Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.
Zheng R et al.
Cancers, 2020
Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay.
Belloum Y et al.
Cells, 2020
Long-read sequencing for non-small-cell lung cancer genomes.
Sakamoto Y et al.
Genome Research, 2020
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling.
Weber S et al.
Cancers, 2020
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F et al.
Cancer Medicine, 2019
Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W et al.
Molecular Cancer Therapeutics, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A et al.
Bmc Gastroenterology, 2019
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Shaukat I et al.
Human Pathology, 2019
Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
Kordiak J et al.
Journal of Cancer Research and Clinical Oncology, 2019
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.
Grosse C et al.
Plos One, 2019
Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules.
Park E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview.
Sikdar N et al.
Current Genomics, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
ERBB2 mutation: A promising target in non-squamous cervical cancer.
Xiang L et al.
Gynecologic Oncology, 2018
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry.
Bonaparte E et al.
Diagnostic Pathology, 2018
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Kato S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A et al.
Plos Medicine, 2017
Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.
Nastase A et al.
American Journal of Cancer Research, 2017
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J et al.
Lung Cancer (amsterdam, Netherlands), 2016
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P et al.
Clinical Lung Cancer, 2016